Here, we examine whether a customized NanoString panel including genes providing information about COO, MYC/BCL2, and a selection of genes known to predict survival in R‐CHOP‐treated DLBCL can integrate all these sources of information to create a robust and reproducible prognostic score. Here, BCL2 is linked to diffuse large B-cell lymphoma.